This week, the Food and Drug Administration (FDA) escalated the recall of a batch of thyroid tablets produced by Vitruvias Therapeutics Inc. to the highest risk level, cautioning that the medication might "lead to severe health consequences or death."
As reported by Telemundo 51, the federal agency has reclassified the recall as Class I, the most serious category on its scale, which is defined as "a situation where there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
Details on the Affected Product
The recall concerns lot 504950 of Thyroid Tablets, USP 30 mg (NDC code 69680-166-00), with an expiration date of September 30, 2026. A total of 3,655 units from this lot were distributed nationwide in the United States between January 31, 2025, and September 30, 2025, with approximately 1,955 units sold.
The issue detected is that the tablets may be "superpotent," meaning they contain a higher concentration of thyroid hormone than indicated on the label, potentially resulting in patients unknowingly receiving a dose greater than prescribed.
The Dangers of Excessive Dosage
Taking an excessive dose of thyroid hormone can trigger hyperthyroidism, a condition that accelerates metabolism with potentially serious effects. Documented adverse effects include heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heartbeat, and cardiac rhythm disturbances.
The groups most at risk are elderly patients and pregnant women, as excessive thyroid hormone levels can lead to heart problems and maternal-fetal complications. In more severe cases, untreated hyperthyroidism may lead to arrhythmias, atrial fibrillation, heart failure, osteoporosis, or a potentially life-threatening thyrotoxic crisis.
Guidance for Affected Patients
Vitruvias Therapeutics has stated that it is "proactively notifying its wholesalers via email and phone to halt the distribution of the product" and is coordinating the destruction of the recalled tablets. However, the pharmaceutical company expressly warned patients not to stop their treatment without consulting their doctor first, as abruptly discontinuing medication for hypothyroidism can also have health consequences.
At the time of the initial announcement in August, the company reported no adverse health events linked to this batch.
A Year Marked by Thyroid Medication Issues
This recall is not an isolated incident. In July 2026, Major Pharmaceuticals issued another recall for levothyroxine sodium tablets for being "subpotent," classified by the FDA as Class II, covering dosages of 25, 50, 75, 88, 112, 125, and 150 micrograms.
The difference between the two cases is significant: a subpotent medication fails to adequately treat hypothyroidism, whereas a superpotent one can cause hormonal overdose with immediate and potentially deadly effects, hence the Class I classification for Vitruvias.
The FDA classifies recalls into three levels: Class I (highest risk), Class II (moderate risk, reversible effects), and Class III (lowest risk). The elevation to Class I is relatively rare, indicating that the agency considers the danger to be immediate and serious.
Those who believe they possess tablets from Vitruvias Therapeutics' lot 504950 should consult the official FDA registry and contact their physician before making any decisions regarding their treatment.
FAQs about the FDA's Highest-Risk Alert for Thyroid Pills
What is the main reason for the recall of the thyroid pills by the FDA?
The recall was issued because the thyroid pills are suspected to be "superpotent," containing a higher concentration of hormone than indicated, which could lead to severe health consequences or death.
What should patients do if they have been taking the affected thyroid medication?
Patients should not discontinue their treatment abruptly. They are advised to consult their doctor for guidance on how to proceed safely with their medication.
How does the FDA classify product recalls?
The FDA classifies recalls into three categories: Class I (highest risk), Class II (moderate risk with reversible effects), and Class III (lowest risk).